Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KMT2A rearrange |
Therapy | Revumenib |
Indication/Tumor Type | T-cell acute lymphoblastic leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | T-cell acute lymphoblastic leukemia | sensitive | Revumenib | Guideline | Actionable | Revuforj (revumenib) is included in guidelines for patients with relapsed or refractory T-cell acute lymphoblastic leukemia harboring a KMT2A rearrangement (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... |